Several markers have been identified for the prostate, including PSA, which performs poorly in the diagnosis of mild to advanced prostate cancer, prostate-specific membrane antigen (PSMA) is used to identify metastatic cells and is intended as a target for mAb and other immunological therapies. Here, FOLH1 is linked to prostate carcinoma.